Saumil Mehta, MD
Internal Medicine · Plano, TXNPI 1194740381
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 44 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 18 manufacturers reported payments, led by AbbVie at 31.2% of the total. Reporting peaked in 2019 at $229 and has fallen 85.7% since, to $33 in 2025.
Across 44 payments — averaging $17.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$236
- Johnson & Johnson$117
- Neurocrine Biosciences, Inc.$67
- Corium, LLC$62
- Tris Pharma Inc$38
- Neuronetics, Inc.$38
- plus $197 from 12 others
Across 330 payments — averaging $16,338 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Modernatx, Inc.$3.5M
- Pfizer$929K
- AbbVie$431K
- Corium, LLC$275K
- GSK$115K
- IBSA Institut Biochimique SA$53K
- plus $131K from 7 others
What the payments were for
- Food & beverage$756100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 14 | $236 |
| Johnson & Johnson | 6 | $117 |
| Neurocrine Biosciences, Inc. | 3 | $67 |
| Corium, LLC | 4 | $62 |
| Tris Pharma Inc | 2 | $38 |
| Neuronetics, Inc. | 2 | $38 |
| Almatica Pharma LLC | 2 | $29 |
| Livanova USA, Inc. | 1 | $18 |
| Bausch Health US, LLC | 1 | $17 |
| Dexcom, Inc. | 1 | $17 |
| Otsuka America Pharmaceutical, Inc. | 1 | $17 |
| Adlon Therapeutics L.p. | 1 | $16 |
| Arbor Pharmaceuticals, Inc. | 1 | $14 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $14 |
| Jazz Pharmaceuticals Inc. | 1 | $14 |
| Eisai Inc. | 1 | $14 |
| Sage Therapeutics, LLC | 1 | $14 |
| Alkermes, Inc. | 1 | $12 |
How this compares
$756 in reported general payments places this provider in the 65th percentile of 7,675 internal medicine providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JanuviaSitagliptin Phosphate | 33 | $42,191 |
| JardianceEmpagliflozin | 35 | $38,345 |
| TrulicityDulaglutide | 13 | $23,821 |
| EliquisApixaban | 20 | $20,500 |
| OzempicSemaglutide | 14 | $17,238 |
| Humalog Kwikpen U-200Insulin Lispro | 11 | $12,869 |
| TradjentaLinagliptin | 12 | $12,088 |
| Breo ElliptaFluticasone/Vilanterol | 15 | $7,285 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 15 | $2,936 |
| Novolog FlexpenInsulin Aspart | 21 | $2,790 |
| Gabapentin | 103 | $1,980 |
| Levothyroxine Sodium | 131 | $1,026 |
| Atorvastatin Calcium | 148 | $949 |
| Potassium Chloride | 31 | $707 |
| Mirtazapine | 21 | $699 |
Paid to pharmacies, not to this prescriber.
Other internal medicine in Plano
- Ayesha AmanPlano$133K
- Spencer BerthelsenSugar Land$891K
- Hameed AliTemple$773K
- Marc TribbleDallas$693K
- Gary SinclairDallas$599K
- Mohammed Al-NajjarEl Paso$586K
- Han SchmidlyDallas$465K
- Hussein TawbiHouston$365K
- Hans LeeHouston$327K
- Tapan KadiaHouston$311K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.